A 24-Week, Double-Blind, Randomized, Parallel-Group, Study of the Efficacy and Safety of 3 Oral Doses of AVE1625 on Top of Either Olanzapine, Risperidone/Paliperidone, Quetiapine or Aripiprazole in the Treatment of Cognitive Impairment in Schizophrenia

Trial Profile

A 24-Week, Double-Blind, Randomized, Parallel-Group, Study of the Efficacy and Safety of 3 Oral Doses of AVE1625 on Top of Either Olanzapine, Risperidone/Paliperidone, Quetiapine or Aripiprazole in the Treatment of Cognitive Impairment in Schizophrenia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 May 2016

At a glance

  • Drugs Drinabant (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms CONNECT
  • Sponsors Sanofi
  • Most Recent Events

    • 18 May 2010 Planned end date changed from 1 Oct 2009 to 1 Sep 2009 as reported by ClinicalTrials.gov.
    • 18 May 2010 Actual patient number (873) added as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top